Life Sciences

Federal regulators formally rejected Genzyme's multiple sclerosis (MS) treatment over concerns about trial design and potentially serious side effects, the Cambridge-based drug maker said Monday.

Cambridge-based Genzyme has agreed to pay $22.28 million to resolve allegations brought by former employees that the biotechnology giant marketed an inappropriate use for a surgery medication, the U.S. Department of Justice said.

RXi Pharmaceuticals of Westborough has signed a five-year lease for 7,581 square feet of office and laboratory space in Marlborough, according to a filing Friday with the U.S. Securities and Exchange Commission.

Karyopharm Therapeutics, a clinical-stage pharmaceutical company in Natick, has been added to the Russell 3000 and Russell 2000 indices as part of Russell Investments' fourth-quarter additions of companies that launched initial public offerings of stock, Karyopharm announced.

Eight public high schools in Central Massachusetts received a combined $685,000 to purchase life sciences training equipment and supplies, the Patrick administration and the Massachusetts Life Sciences Center (MLSC) announced today.

A new report sponsored by biotechnology industry groups and conducted by PricewaterhouseCoopers says Worcester's long manufacturing history and affordable cost of living help position the city as a manufacturing center for biopharmaceutical products, avoiding the need to send that work elsewhere.

A Gardner firm and a cancer research center in Canada have launched a new biotechnology company that hopes to create about a dozen jobs over the next three years.

A panel of medical experts recommended Wednesday that federal health regulators approve Boston Scientific's stroke-prevention device.

Pharmaceutical startup Karyopharm Therapeutics of Natick said underwriters for its initial public offering of common stock have exercised their option to buy more than a million additional shares.

A researcher said AbbVie's experimental drug for leukemia strongly reduced signs of the disease in 84 percent of patients.